ASAP1 promotes extrahepatic cholangiocarcinoma progression by regulating the Wnt/β-catenin pathway in vitro and in vivo.

IF 3.6 3区医学 Q2 ONCOLOGY

American journal of cancer research Pub Date : 2024-11-15 eCollection Date: 2024-01-01 DOI:10.62347/RKQX3504

Jiaqi He, Han Liu, Jianhua Cai, Sheng Shen, Jiwen Wang, Houbao Liu

{"title":"ASAP1 promotes extrahepatic cholangiocarcinoma progression by regulating the Wnt/β-catenin pathway in vitro and in vivo.","authors":"Jiaqi He, Han Liu, Jianhua Cai, Sheng Shen, Jiwen Wang, Houbao Liu","doi":"10.62347/RKQX3504","DOIUrl":null,"url":null,"abstract":"This study sought to identify the relationship between ADP-ribosylation factor GTPase-activating protein (ASAP1) expression and clinical outcomes in extrahepatic cholangiocarcinoma (EHCC) patients. Quantitative real-time PCR (qRT-PCR), Western blotting, and immunohistochemistry were used to analyze the expression of ASAP1 in cholangiocarcinoma (CC) tissue samples and cell lines. The survival rate and clinicopathological characteristics of CC patients were also examined. Cell Counting Kit-8 (CCK-8) and 5-ethynyl-2'-deoxyuridine (EdU) assays were used to detect cell proliferation. Flow cytometry was used to assess the cell cycle distribution. Both in vitro and in vivo experiments showed that ASAP1 knockdown decreased cell proliferation, inhibited cell cycle progression, and increased apoptosis. ASAP1 regulates Wnt/β-catenin pathway activity in CC, promoting cell migration, and invasion in culture; and promotes tumor development in vivo. ASAP1 plays a key role in EHCC tumor development and could serve as a potential therapeutic target for EHCC.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 11","pages":"5178-5192"},"PeriodicalIF":3.6000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626284/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/RKQX3504","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This study sought to identify the relationship between ADP-ribosylation factor GTPase-activating protein (ASAP1) expression and clinical outcomes in extrahepatic cholangiocarcinoma (EHCC) patients. Quantitative real-time PCR (qRT-PCR), Western blotting, and immunohistochemistry were used to analyze the expression of ASAP1 in cholangiocarcinoma (CC) tissue samples and cell lines. The survival rate and clinicopathological characteristics of CC patients were also examined. Cell Counting Kit-8 (CCK-8) and 5-ethynyl-2'-deoxyuridine (EdU) assays were used to detect cell proliferation. Flow cytometry was used to assess the cell cycle distribution. Both in vitro and in vivo experiments showed that ASAP1 knockdown decreased cell proliferation, inhibited cell cycle progression, and increased apoptosis. ASAP1 regulates Wnt/β-catenin pathway activity in CC, promoting cell migration, and invasion in culture; and promotes tumor development in vivo. ASAP1 plays a key role in EHCC tumor development and could serve as a potential therapeutic target for EHCC.

查看原文本刊更多论文

在体外和体内，ASAP1通过调节Wnt/β-catenin通路促进肝外胆管癌的进展。

本研究旨在确定肝外胆管癌（EHCC）患者adp -核糖基化因子gtpase激活蛋白（ASAP1）表达与临床预后之间的关系。采用实时荧光定量PCR （qRT-PCR）、Western blotting和免疫组化技术分析ASAP1在胆管癌（CC）组织样本和细胞系中的表达。同时对CC患者的生存率和临床病理特征进行了分析。细胞计数试剂盒-8 （CCK-8）和5-乙基-2′-脱氧尿苷（EdU）检测细胞增殖。流式细胞术检测细胞周期分布。体外和体内实验均表明，ASAP1敲低可降低细胞增殖，抑制细胞周期进展，增加细胞凋亡。ASAP1调节CC中Wnt/β-catenin通路活性，促进细胞迁移和侵袭；并促进体内肿瘤的发展。ASAP1在EHCC肿瘤发展中起关键作用，可能是EHCC的潜在治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of cancer research ONCOLOGY-

自引率

3.80%

发文量

263

期刊介绍： The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.